| Literature DB >> 20335989 |
Satoshi Ohtake1, Tsutomu Arakawa, A Hajime Koyama.
Abstract
Development of effective and environmentally friendly disinfectants, or virucidal agents, should help prevent the spread of infectious diseases through human contact with contaminated surfaces. These agents may also be used, if non-toxic to cells and tissues, as chemotherapeutic agents against infectious diseases. We have shown that arginine has a synergistic effect with a variety of virucidal conditions, namely acidic pH and high temperature, on virus inactivation. All of these treatments are effective, however, at the expense of toxicity. The ability of arginine to lower the effective threshold of these parameters may reduce the occurrence of potential toxic side effects. While it is clear that arginine can be safely used, the mechanism of its virus inactivation has not yet been elucidated. Here we examine the damages that viruses suffer from various physical and chemical stresses and their relations to virus inactivation and aggregation. Based on the relationship between the stress-induced structural damages and the infectivity of a virus, we will propose several plausible mechanisms describing the effects of arginine on virus inactivation using the current knowledge of aqueous arginine solution properties.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20335989 PMCID: PMC6257253 DOI: 10.3390/molecules15031408
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1In vitro inactivation of HSV-2 by acidic solvents as a function of pH.
Figure 2Inactivation of HSV-1 by arginine at neutral pH as a function of temperature.
Temperature of 50 and 90% virus inactivation with either aqueous arginine or NaCl solution buffered with 10 mM phosphate, pH 7.0. The concentration of both arginine and NaCl are indicated in the table.
| Solvent | Temperature at 50% inactivation | Temperature at 90% inactivation | ||
|---|---|---|---|---|
| 0 (PBS) | 47 | 50 | ||
| Arginine | NaCl | Arginine | NaCl | |
| 0.5 M | -2 | 0 | -3 | |
| 0.75 M | -7 | -4 | -5 | -2 |
| 1.0 M | -10 | -6 | -10 | |
| 1.2 M | -17 | -7 | -16 | -4 |
HSV-1 was incubated for 5 min with arginine solution at pH 7.0 at the indicated concentration. The data are extracted from Figure 2. Inactivation temperature in PBS (phosphate-buffered saline) was subtracted from the temperature in test solvents. Reformatted from reference [12].
Figure 3Virus inactivation mechanism-1: synergistic effect of arginine with other stresses causes structural changes in viral spike proteins leading to aggregation.
Figure 4Virus inactivation mechanism-2: arginine in the presence of other stresses causes aggregation or dissociation of virus particles depending on their initial physical state.
Figure 5Virus inactivation mechanism-3: synergistic effect of arginine with other stresses causes pore formation in the lipidic viral envelope.
Change in melting temperature.
| Arginine Concentration / M | Lysozyme/°C | RNase/°C |
|---|---|---|
| 0.1 | 0 | 0 |
| 0.2 | -1 | |
| 0.5 | -1 | -1 |
| 1.0 | -1 | -3 |
| 2.0 | 0 | -3 |
Melting temperature was determined from the temperature dependent absorbance changes as described in the original manuscript [14]. Melting temperature in the absence of arginine was subtracted from that in the test solvents. RNase, ribonuclease. Reformatted from reference [14].
Figure 6High affinity binding of specific antiviral drug and weak arginine binding.